PP
ARGS

Paloma Partners’s Argos Therapeutics, Inc. ARGS Stock Holding History

Paloma Partners’s Portfolio ARGS Stock Details ARGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2,305
Closed -$17K – 2728
2017
Q2 		$17K Buy
+2,305
New +$19.6K ﹤0.01% 2117
2014
Q3 		– Sell
-897
Closed -$144K – 1599
2014
Q2 		$144K Buy
+897
New +$148K 0.01% 1008

Other funds holding ARGS

PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
KeyBank National Association
KeyBank National Association Cleveland, Ohio $30.4B AUM 27.51% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Paloma Partners's ARGS Position: Q3 2017 in Review

Paloma Partners sold out of Argos Therapeutics, Inc. (ARGS) in Q3 2017, closing a stake of 2,305 shares — an estimated $17K sold.

Paloma Partners first reported a position in ARGS in Q2 2014 and held it in 2 quarters. The position peaked at $144K in Q2 2014. 29 funds tracked by Wall St. Rank hold ARGS as of Q3 2017.

  • Paloma Partners reported no remaining Argos Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
  • Paloma Partners sold 2,305 Argos Therapeutics, Inc. shares in Q3 2017, an estimated $17K.
  • Paloma Partners first reported a position in Argos Therapeutics, Inc. in Q2 2014 and held it in 2 quarters.
  • Paloma Partners's Argos Therapeutics, Inc. position peaked at $144K in Q2 2014.
  • 29 funds tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q3 2017.

Based on Paloma Partners's 13F filing for Q3 2017, filed 14 Nov 2017.